Loading clinical trials...
Loading clinical trials...
A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination With Paclitaxel vs. Paclitaxel Alone in Patients With Metastatic or Locally Recurrent Breast Cancer
Conditions
Interventions
Paclitaxel
Alisertib
Locations
1
United States
22 Sites
Including Dallas and Austin, Texas, United States
Start Date
February 12, 2015
Primary Completion Date
April 11, 2024
Completion Date
August 1, 2024
Last Updated
October 9, 2024
NCT05468034
NCT04541381
NCT03137095
NCT06393374
NCT04852887
NCT07547774
Lead Sponsor
US Oncology Research
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions